Navigation Links
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Date:8/19/2007

MARIETTA, Ga., Aug. 10 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today the receipt of an action letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for bifeprunox, an atypical antipsychotic that was reviewed for the acute treatment of schizophrenia, as well as the maintenance of stable adult patients. The Agency stated that the drug was not approvable at this time.

The FDA stated in the letter that bifeprunox demonstrated effectiveness in the long-term maintenance study and indicated that a second positive maintenance study could be sufficient to support a maintenance claim for bifeprunox. The Companies believe that bifeprunox offers distinct benefits for the long-term maintenance of patients with schizophrenia. The Companies will meet with the FDA to discuss the study design and to assess how this additional study combined with ongoing and planned studies can support a maintenance indication.

Although the FDA acknowledged that bifeprunox separated from placebo in two short-term studies in the acute setting, the Agency concluded that the efficacy data, when compared to reference drugs, were not sufficient for approval.

The Agency also requested further information regarding human metabolism of bifeprunox, and information regarding a complex case of a patient who died while participating in one of the trials.

"We believe that bifeprunox is a promising drug for the treatment of schizophrenia, and that there is a need for new treatment options to help people with schizophrenia manage their disease," says Laurence Downey, M.D., President and CEO of Solvay Pharmaceuticals, Inc. "
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Reportlinker.com announces that a new market research ... Global Patient Scales Industry ... worldwide markets for Patient Scales in US$ Thousand ... & Baby Scales, Chair Scales, and Under Bed ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... announced last Thursday, August 14, 2014, has closed.  The ... convertible at $7.30 per share of common stock.  The ... to purchase up to an additional 30% of these ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
(Date:8/20/2014)... 20, 2014 In its latest blog post, ... treatment program that gets clients off to a great start ... believe in, is highlighting an important and possibly life-changing – ... everyone who wants to understand the insidious nature of drug ... belief that drug abuse targets a certain socioeconomic group, such ...
(Date:8/20/2014)... Texas Medical Research Associates is looking for ... help test the effectiveness of a new drug looking to ... be eligible to participate in the study. , According to ... can lead to cardiovascular disease, the no. 1 cause of ... the risk of heart disease and stroke. People with high ...
(Date:8/20/2014)... sleep may wake up to worse consequences than nodding ... of being obese by age 21 was 20 percent ... of sleep a night, compared with their peers who ... Control and Prevention recommends nine to ten hours of ... of Public Health at Columbia University and the University ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 According to ... on August 7 in the multicounty litigation (MCL) case ... RE DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly ... have been dismissed without prejudice. The cases enumerated in ... of being resolved.” The Rottenstein Law Group LLP, a ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
Breaking Medicine News(10 mins):Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Texas Medical Research Associates Announce New Study 2Health News:Teen sleeplessness piles on risk for obesity 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3
... The American Journal of Gastroenterology suggests that smoking may ... in those// who suffer from Crohn’s disease. Where the ... eventually require surgical treatment. ,“In patients who ... the small intestine, rather than the colon,” says study ...
... cold may cause uncommon ailments if neglected, specialists warn. // ... have always thought it is harmless. But specialists say it ... also negatively impact vision or cause harm to any part ... cases of chronic sinusitis because of unchecked pollution. Chronic sinus ...
... has been recommended for medical conditions such as endometriosis, ... choice for women who dislike menstruation or find it ... and is it a reasonable lifestyle choice, asks Paula ... ,Birth control options that reduce or eliminate periods ...
... new cancer research study that may be the ‘last best ... to discover the genetic and environmental factors that cause and ... aims to enroll a geographically and ethnically diverse group of ... pave the way for the next generation of American Cancer ...
... the counter (OTC) drugs can be highly addictive, warn two ... of dependency on OTC drugs is often forgotten, write Drs ... months, they describe seeing three patients with addictions to Nurofen ... started using the product for its approved indications, but their ...
... benefit from having a tonsillectomy in the short term, ... and any benefits have to be balanced against the ... small study of adults from Finland showed that tonsillectomy ... days, compared with watchful waiting. ,But despite ...
Cached Medicine News:Health News:A Cold Shoulder to Cold - At Your Risk 2Health News:Should Menstrual Suppression Be a Lifestyle Choice? 2Health News:American Cancer Society Launches Major New Study 2Health News:American Cancer Society Launches Major New Study 3Health News:Is It Worth Having Surgery to Remove Your Tonsils? 2
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
Inquire...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Medicine Products: